Zaki, M.G.; Jakova, E.; Pordeli, M.; Setork, E.; Taghibiglou, C.; Cayabyab, F.S.
The Anti-Parkinsonian A2A Receptor Antagonist Istradefylline (KW-6002) Attenuates Behavioral Abnormalities, Neuroinflammation, and Neurodegeneration in Cerebral Ischemia: An Adenosinergic Signaling Link Between Stroke and Parkinson’s Disease. Int. J. Mol. Sci. 2025, 26, 5680.
https://doi.org/10.3390/ijms26125680
AMA Style
Zaki MG, Jakova E, Pordeli M, Setork E, Taghibiglou C, Cayabyab FS.
The Anti-Parkinsonian A2A Receptor Antagonist Istradefylline (KW-6002) Attenuates Behavioral Abnormalities, Neuroinflammation, and Neurodegeneration in Cerebral Ischemia: An Adenosinergic Signaling Link Between Stroke and Parkinson’s Disease. International Journal of Molecular Sciences. 2025; 26(12):5680.
https://doi.org/10.3390/ijms26125680
Chicago/Turabian Style
Zaki, Michael G., Elisabet Jakova, Mahboubeh Pordeli, Elina Setork, Changiz Taghibiglou, and Francisco S. Cayabyab.
2025. "The Anti-Parkinsonian A2A Receptor Antagonist Istradefylline (KW-6002) Attenuates Behavioral Abnormalities, Neuroinflammation, and Neurodegeneration in Cerebral Ischemia: An Adenosinergic Signaling Link Between Stroke and Parkinson’s Disease" International Journal of Molecular Sciences 26, no. 12: 5680.
https://doi.org/10.3390/ijms26125680
APA Style
Zaki, M. G., Jakova, E., Pordeli, M., Setork, E., Taghibiglou, C., & Cayabyab, F. S.
(2025). The Anti-Parkinsonian A2A Receptor Antagonist Istradefylline (KW-6002) Attenuates Behavioral Abnormalities, Neuroinflammation, and Neurodegeneration in Cerebral Ischemia: An Adenosinergic Signaling Link Between Stroke and Parkinson’s Disease. International Journal of Molecular Sciences, 26(12), 5680.
https://doi.org/10.3390/ijms26125680
